PERIPHERAL T-CELL LYMPHOMA (PTCL)
Clinical trials for PERIPHERAL T-CELL LYMPHOMA (PTCL) explained in plain language.
Never miss a new study
Get alerted when new PERIPHERAL T-CELL LYMPHOMA (PTCL) trials appear
Sign up with your email to follow new studies for PERIPHERAL T-CELL LYMPHOMA (PTCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill shows promise in early trial for Hard-to-Treat blood cancers
Disease control Recruiting nowThis study tests a new oral drug called AZD3470 in people with certain blood cancers, including Hodgkin and non-Hodgkin lymphoma. The goal is to see if the drug is safe and works, either alone or with other cancer treatments. About 161 adults and adolescents will take part in thi…
Matched conditions: PERIPHERAL T-CELL LYMPHOMA (PTCL)
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 16, 2026 23:50 UTC
-
Engineered immune cells take on Hard-to-Treat lymphoma
Disease control Recruiting nowThis early-phase trial tests a personalized cell therapy for people with a specific type of lymphoma linked to the Epstein-Barr virus (EBV). The treatment uses the patient's own immune cells, modified to recognize and attack EBV-infected cancer cells. The study aims to find a saf…
Matched conditions: PERIPHERAL T-CELL LYMPHOMA (PTCL)
Phase: EARLY_PHASE1 • Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated May 11, 2026 20:53 UTC